Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 58.15

+5.4%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (10512)	2/19/2004 4:35:28 PM
From: Icebrg	of 52153

>>Anyone follow this program?>> I used to, but not any more. Their trials take forever and ever. They have seen some interesting results in both pancreatic cancer and melanoma too. The lung cancer program used to be partnered with Japan Tobacco, but they have now withdrawn and returned their rights to CEGE. From my point of view it is interesting that Cell Genesys and Medarex have said that they will soon start up a trial combining GVAX and MDX-010. There were some interesting results in malignant melanoma with MDX-010 from patients who previously had been treated with GVAX. Using both CM-CSF-spiked cancer cells and anti-CTLA-4 should sharpen the attack. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next